DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robertson, P.
Right arrow Articles by Parkinson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, P.
Right arrow Articles by Parkinson, A.

Vol. 28, Issue 6, 664-671, June 2000

In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil

Philmore Robertson, Heleen H. DeCory,1 Ajay Madan, and Andrew Parkinson

Department of Drug Safety and Disposition, Cephalon, Inc., West Chester, Pennsylvania (P.R., H.H.); and XenoTech, L.L.C., Kansas City, Kansas (A.M., A.P.)

The ability of modafinil to affect human hepatic cytochrome P450 (CYP) activities was examined in vitro. The potential for inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 by modafinil (5-250 µM) was evaluated with pooled human liver microsomes. Modafinil exhibited minimal capacity to inhibit any CYP enzyme, except CYP2C19. Modafinil inhibited the 4'-hydroxylation of S-mephenytoin, a marker substrate for CYP2C19, reversibly and competitively with a Ki value of 39 µM, which approximates the steady-state Cmax value of modafinil in human plasma at a dosage of 400 mg/day. No irreversible inhibition of any CYP enzyme was observed, and there was no evidence of metabolism-dependent inhibition. The potential for induction of CYP activity was evaluated by exposing primary cultures of human hepatocytes to modafinil (10-300 µM). Microsomes were then prepared and assayed for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 activities. The mean activities of microsomal CYP1A2, CYP2B6, and CYP3A4/5 from modafinil-treated hepatocytes were higher (up to 2-fold) than those in the solvent-treated controls but were less than those produced by reference inducers of these enzymes. At high concentrations of modafinil (>= 100 µM), the mean activity of CYP2C9 was decreased (up to 60%) relative to that in the solvent controls. Overall, modafinil was shown to have effects on human hepatic CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 activities in vitro. Although effects obtained in vitro are not always predictive of effects in vivo, such results provide a rational basis for understanding drug-drug interactions that are observed clinically and for planning subsequent investigations.

1 Current address: Department of Pharmacology and Physiology, University of Rochester, Rochester, NY 14642.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
B. L. Paris, B. W. Ogilvie, J. A. Scheinkoenig, F. Ndikum-Moffor, R. Gibson, and A. Parkinson
In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran
Drug Metab. Dispos., October 1, 2009; 37(10): 2045 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A.-E. F. Nassar, I. King, B. L. Paris, L. Haupt, F. Ndikum-Moffor, R. Campbell, E. Usuki, J. Skibbe, D. Brobst, B. W. Ogilvie, et al.
An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes
Drug Metab. Dispos., September 1, 2009; 37(9): 1922 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Richert, G. Tuschl, C. Viollon-Abadie, N. Blanchard, A. Bonet, B. Heyd, N. Halkic, E. Wimmer, H. Dolgos, and S. O. Mueller
Species Differences in the Response of Liver Drug-Metabolizing Enzymes to (S)-4-O-Tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric Acid (EMD 392949) in Vivo and in Vitro
Drug Metab. Dispos., April 1, 2008; 36(4): 702 - 714.
[Abstract] [Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 Drug Metab. Dispos.Home page
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson
GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS
Drug Metab. Dispos., January 1, 2006; 34(1): 191 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. Hukkanen, P. Jacob III, and N. L. Benowitz
Metabolism and Disposition Kinetics of Nicotine
Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al.
Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes
Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. R. DEQUARDO
Modafinil-Associated Clozapine Toxicity
Am J Psychiatry, July 1, 2002; 159(7): 1243 - 1244.
[Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.